These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14726661)

  • 1. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.
    Hobdy EM; Kraut E; Masters G; Blum K; McKeon A; Byrd B; Davies M; Beaulieu N; Murren JR
    Cancer Biol Ther; 2004 Jan; 3(1):89-93. PubMed ID: 14726661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
    Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
    Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
    Bryce AH; Mattar B; Hillman SL; Adjei AA; Kugler JW; Rowland K; Wender DB; Soori G; Perez EA; Jett JR
    Am J Clin Oncol; 2010 Aug; 33(4):353-7. PubMed ID: 19935387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.
    Felip E; Rosell R; Domine M; Santomé L; Garrido P; Font A; Carrato A; Terrasa J; Vadell C; Mañe JM; Baselga J;
    Ann Oncol; 2003 Oct; 14(10):1549-54. PubMed ID: 14504057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
    Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy versus best supportive care for extensive small cell lung cancer.
    Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD001990. PubMed ID: 24282143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
    Ramalingam S; Belani CP; Day R; Zamboni BA; Jacobs SA; Jett JR
    Ann Oncol; 2004 Feb; 15(2):247-51. PubMed ID: 14760117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.